Predictive AI has been selected for the 'Deep Tech TIPS' program hosted by the Ministry of SMEs and Startups. Deep Tech TIPS is a project that selects startups with outstanding technological capabilities and supports their technological development as part of the '1,000+ Ultra-Gap Startups' project led by the Ministry of SMEs and Startups. Predictive AI possesses technology to diagnose high-risk diseases in advance using genome-based digital twin technology, and was selected in the bio and health field after receiving investment and recommendation from the Gyeonggi Center for Creative Economy and Innovation, the operator of TIPS.
Predictive AI is a startup founded in September 2023 by twin brothers, CEO Sa-joong Yoon and CSO Si-joong Yoon, who are both genomics and bio experts and adjunct professors at Johns Hopkins University in the United States. In the early stages of the startup, it attracted investments from Naver D2SF, Hana Securities, and Muir Woods Ventures.
Recently, Predictive AI has been expanding its business scope by developing a POCT (Point-of-Care Testing) system that can diagnose cancer early by utilizing liquid biopsy technology that detects DNA fragments of cancer cells. With this selection by DeepTech Tips, Predictive AI will receive up to 1.7 billion won in funding over the next three years and will develop and commercialize digital twin technology specialized in early diagnosis and monitoring of blood cancer.
Jaehoon Shim, team leader at the Gyeonggi Center for Creative Economy and Innovation, said, “Predictive AI possesses excellent biodata technology on a global level, and boasts particularly outstanding capabilities in the fields of genome and DX, which is why we recommended them for the Deep Tech Tips program.”
“By being selected as DeepTech Tips, we have secured additional business funds, which will allow us to further advance our genome-based AI technology,” said Yoon Sa-joong, CEO of PredictiveAI. “PredictiveAI will become a company that provides anyone with sufficient information about the treatment process and helps them make effective drug choices based on genome information and medical data.”
You must be logged in to post a comment.